The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas
J. Erika Haydu, Jeremy S. Abramson
Abstract
ABSTRACT: T-cell engaging-therapies have transformed the treatment landscape of relapsed and refractory B-cell non-Hodgkin lymphomas by offering highly effective treatments for patients with historically limited therapeutic options. This review focuses on the advances in chimeric antigen receptor-modified T cells and bispecific antibodies, first providing an overview of each product type, followed by exploring the primary data for currently available products in large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. This review also highlights key logistical and sequencing considerations across diseases and product types that can affect clinical decision-making.
Topics & Concepts
AntibodyCurrent (fluid)State (computer science)B cellCellT cellBispecific antibodyLymphomaCancer researchCell biologyImmunologyMedicineBiologyComputer sciencePhysicsMonoclonal antibodyGeneticsImmune systemAlgorithmThermodynamicsCAR-T cell therapy researchViral Infectious Diseases and Gene Expression in InsectsLymphoma Diagnosis and Treatment